Impact of Intra- and Postoperative Continuous Infusion of Lidocaine on Analgesia in Vascular Anaesthesia
NCT ID: NCT04691726
Last Updated: 2022-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
87 participants
INTERVENTIONAL
2019-01-29
2022-07-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Due to the numerous disease burden of patients and the operational specifics, the use of multimodal therapy in the management of pain is of particular importance, as the use of high doses of opioids improves hemodynamic stability, but at the same time affects the occurrence of side effects - mainly excessive sedation, respiratory disorders, hypoventilation and, consequently, for hypoxia of the heart muscle. The risk of myocardial injury in non-cardiac surgery (MINS) is significant in the light of the available literature.
Lidocaine used in intravenous infusion is one of the recommended components of multidirectional analgesia. Its adjuvant properties make it possible to reduce the amount of opioid drugs used, and thus - to reduce the frequency of their side effects. The high effectiveness of such a procedure has been proven in numerous experimental and epidemiological studies. Due to the low frequency of side effects associated with its use, the therapy has a strong recommendation for use in relieving perioperative pain. The analysis of the literature on the subject shows that there is little data assessing effectiveness of lidocaine infusion in relation to the group of patients after surgery on the abdominal aorta.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Anaesthesia will be performed by anesthetist experienced in vascular surgery. Every patient will be premedicated with midazolam (3,75mg-15 mg orally), adjusted to his/her body weight. Premedication efficacy will be assessed before induction using RASS scale (Richmond Agitation-Sedation Scale).
During induction of anaesthesia: fentanyl (0,01-0,02 mg / kg i.v.), propofol (1-2 mg/kg i.v.), atrakurium (0,5 mg/kg i.v.) will be given. Depth of anaesthesia will be monitored with BIS index (bi-spectral index) or entropy till the emergence. Patients scoring above 2 points in APFEL scale will receive antiemetic drug - ondansetron 8 mg i.v..
Intraoperative monitoring will consist of: non-invasive (NIBP) or invasive blood pressure monitoring (IBP), anesthetic agent concentration monitoring (MAC, minimal alveolar concentration), pulse oximetry (SpO2), capnometry (etCO2) and anesthetic depth monitoring as above.
During co-induction mechanical ventilation will be performed in CMV mode (controlled mechanical ventilation). Breathing frequency will be adjusted to etCO2 values. Tidal volume will be set on 6-8 ml/ kg IBW (ideal body weight) and positive end-expiratory pressure set on 5 cm H2O. Fresh gases flow mixture will be adjusted according to SpO2 92-100% values. After induction, desflurane will be used in concentrations maintaining depth of anaesthesia between 40-60 BIS/entropy values. In case of BIS/entropy values out of the range during anesthesia, all the events and duration time will be recorded. After general anesthesia mean anesthetic concentration will be counted and recorded.
All participants apart from medication used to perform general anaesthesia will receive 1g of paracetamol i.v. before induction as preemptive analgesia and intravenous bolus of the "tested drug" in the volume of 0,15 ml/kg IBW given over 1-2 minutes, followed by continuous infusion of "tested drug" with ratio of 0,2 ml/kg IBW/h intraoperatively. Postoperatively infusion will be continued with ratio 0,1ml/kg IBW/h for the next 24 hours. According to patient's assignment syringe " tested drug" will contain 1% lidocaine in group A or normal saline in group B.
Titrated doses of 0,05 mg of fentanyl i.v. will be administered as intraoperative analgesic medication. Final dose of fentanyl used during general anaesthesia will be recorded and then changed to the equivalent dose of morphine.
Blood pressure measurements will be taken every 5 minutes to assess hemodynamic stability. Initial value of patient's systolic blood pressure (SBP) and mean arterial pressure (MAP) in the operating theater will be recorded. SBP within the range from 100 to 160 mmHg and MAP \>70 mmHg will be regarded as a target value (TV). In case of sudden increase in BP or HR within TV values associated with painful stimulation from operating field (assessed by experienced anesthetist), titrated dose of fentanyl will be given.
To maintain hemodynamic stability:
1. In case of decrease in BP or MAP below the TV limit: fluid challenge iv with balanced crystalloids will be commenced, especially in case of pulseoximetry or IBP wave variation. If the patient is not responding to fluid challenge, ephedrine in titrated doses of 5-10 mg will be given intravenously to maximal dose of 25 mg. If still ineffective, continues infusion of noradrenaline will be commenced.
2. In case of increase SBP above the limit: if painful response present, i.v. bolus of fentanyl in titrated doses will be given to maximal dose of 0,2 mg to achieve BP decrease to the TV. If ineffective, start re-assessment: painful stimulation present - FNT iv, no painful stimulation - urapidyl in titrated doses of 5 mg iv administered to the effect.
3. In case of increase in SBP or MAP above the limit associated with the clamping of aorta, urapidyl can be given in titrated doses as above.
Final decision regarding maintenance of hemodynamic stability in association with clinical context will be up to the anesthetist.
The number of hemodynamic interventions, BP values, total time out of the range and intraoperative fluid therapy (total amount and type of fluids, blood products), total dose of vasoactive medication will be recorded.
Postoperative care After the surgery, patients will be transferred to post surgical high-dependency unit (HDU). Proper analgesic treatment will be continued. Infusion of "tested drug" will be stopped 24 hours after the surgery.
Visual Analog Scale will be used to assess efficiency of analgesic treatment every 4 hours, with target value \<4 points. Analgesia in postoperative period will consist of: continues infusion of opiate (morphine) rate adjusted according to titration method, metamizole 2,5g i.v. BD and continues infusion of "tested drug" (1% lidocaine or normal saline according to the assignment).
In case of pain exceeding 4 points in VAS scale, patient will receive bolus of 3 mg of morphine i.v., with reassessment after 15 minutes. If no improvement is obtained, second bolus of 3 mg of morphine i.v. will be administered followed by increase in the morphine infusion rate by 1 mg/h.
Any side effects in postoperative period especially associated with analgesic medication, will be recorded (according to Summary Product Characteristics, 24 hours observation), cardiovascular complications (death related to cardiovascular problems, non-fatal acute coronary syndrome; 30 days observation), incidence of post-operative delirium (POD, assessment with CAM or CAM-ICU scale, Confusion Assessment Method or Confusion Assessment Method in Intensive care Unit, 24 hour observation) Statistical analysis Statistical analysis will be performed with the use of the StatsDirect 3.1 program. The nature of the variables is verified by the Shapiro-Wilk test and the evaluation of quantile-quantile charts. Quantitative variables will be presented as arithmetic mean and standard deviation (SD) or median and interquartile range (IQR, interquartilerange). Qualitative variables are presented in the form of absolute values and percentage. The assessment of differences between the groups for quantitative variables will be performed using the Student's t-test with the variance assessment or the Mann-Whitney U test. For qualitative variables, contingency tables and a chi-square test will be used. The criterion of statistical significance is set at p˂0,05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lidocaine infusion
Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 2 mg/kg IBW i.v., continuous infusion of 1% lidocaine postoperatively rate 1 mg/kg IBW i.v. for 24 hours
lidocaine 10mg/ml
bolus i.v. + continuous i.v. infusion
Metamizole
2,5 g i.v. BD
Morphine
continuous i.v. infusion adjusted to VAS scale score
Saline infusion
equal volumes of placebo - 0,9% saline i.v.
Placebo
bolus i.v. + continuous i.v. infusion
Metamizole
2,5 g i.v. BD
Morphine
continuous i.v. infusion adjusted to VAS scale score
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lidocaine 10mg/ml
bolus i.v. + continuous i.v. infusion
Placebo
bolus i.v. + continuous i.v. infusion
Metamizole
2,5 g i.v. BD
Morphine
continuous i.v. infusion adjusted to VAS scale score
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Vascular surgery on aorta or iliac artery
* Proximal anasthomosis of a by-pass in the abdominal cavity
Exclusion Criteria
* Preoperative administration of any pain relief medication in patient, especially opioides (excluding pre-analgesia)
* Heart block second or third-degree, previous pacemaker implantation, chronic atrial fibrillation
* Antiarrhythmic medication on regular basis (excluding b-blockers prescribed due to coronary artery disease)
* Other health problems: chronic heart failure (ejection fraction LVEF\<30%), epilepsy or any episode of seizure, chronic renal failure (AKIN 3-5), chronic liver failure ( class B or C in the Child-Pugh classification), Myasthenia gravis, hypoproteinemia,
* Cognitive or mental dysfunction, that prevents proper cooperation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Łukasz Krzych
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Łukasz Krzych
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Łukasz J Krzych, Professor
Role: STUDY_DIRECTOR
Medical University of Silesia, Katowice
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leszek Giec Upper-Silesia Medical Center of the Medical University of Silesia in Katowice
Katowice, , Poland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gajniak D, Mendrala K, Konig-Widuch G, Parzonka S, Gierek D, Krzych LJ. Effect of lidocaine on intraoperative blood pressure variability in patients undergoing major vascular surgery. BMC Anesthesiol. 2024 May 7;24(1):170. doi: 10.1186/s12871-024-02550-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCM
Identifier Type: -
Identifier Source: org_study_id